$AXON should be in around $150 right now. Their growth, revenue, outlook, just exploding up. Can't say enough great things about them. All law enforcement agencies have been partnering with AXON for good reason, they are leading the industry. FATCS
The house just passed the VA Police Force Improvement and Accountability Act (H.R. 2429) on a bipartisan basis. "would shed a light on use of force by the department’s 4,000 officers and institute other transparency initiatives. It would also require all officers to wear body cameras that record and store audio and video." $AXON is the go-to vender for the federal government and should get this.
Orange County (CA) board of supervisors set to vote on a $12.7mil contract with $AXON on Tuesday for the OC Sheriffs. Should be one more solid and substantial long-term contract in the bag.
$350 Billion of the stimulus package is going to state and local governments. Meaning, they're going to be able to pay for $AXON sooner rather than later. With George Floyd issue back in the news, everyone's minds will be on policing and accountability/video.
Path to $AXON $200: Step 1- beat earnings and increase guidance Step 2- text of George Floyd bill released that includes billions for body cams Step 3- George Floyd act signed into law (May 25th)
There is no other viable competition once the Feds are paying the bills. Axon is THE company of 2021/2022!
$AXON will do what it usually does on a massive earnings beat like this one. it'll pop tomorrow. I'm expecting the stock to hit $150 over the next week, $200 within 52 weeks. Every law enforcement agency using AXON equipment. They're also required to put on cameras and guess what, they use AXON.
AXON's approach to Alz... try to mitigate the adverse effects of donepezil (i.e. Lipstick on Pig)
Excerpt from AXON's Aug 15 PR... it touts its combo technology with donepezil to advance the SoC by reducing the adverse side effects of donepezil. This is no solution for Alz; it's just trying to make donepezil less bad.
"Axovant and Qaam Pharmaceuticals (Qaam) have entered into an exclusive license agreement under which Axovant expects to develop and, if successful, commercialize products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists including glycopyrrolate, which could mitigate the peripheral side effects of cholinesterase inhibitors. Axovant will initially develop RVT-103, a combination of glycopyrrolate and donepezil. In addition, Axovant expects to develop RVT-104, a combination of glycopyrrolate and high-dose rivastigmine. Axovant believes that the intellectual property portfolio licensed from Qaam as part of this transaction provides a strong exclusivity position in this area."
"This program continues to build on our efforts to deliver comprehensive solutions to patients diagnosed with dementia," said Axovant Chief Development Officer Dr. Lawrence Friedhoff, who led the development of Aricept (donepezil) for the treatment of Alzheimer's disease through its approval in 1996. "We believe this product candidate can limit the peripheral side effects of cholinesterase inhibitors which frequently represent an obstacle for patients to adopt or remain on therapy."
Someone should author a hit piece on AXON revealing the truth about its flawed approach on an ineffective SOC, and post it on MF and SA. Seriously! Would like to give AF, JF, CR and the rest of the cabal, who support this lame company, a taste of their own medicine!
L
Hopefully AXON is ready to tank. No good data coming on their already failed drugs. AVXL is the only hope for AD currently
$AXON is the go-to vender for the federal government and should get this.
With George Floyd issue back in the news, everyone's minds will be on policing and accountability/video.
Step 1- beat earnings and increase guidance
Step 2- text of George Floyd bill released that includes billions for body cams
Step 3- George Floyd act signed into law (May 25th)
There is no other viable competition once the Feds are paying the bills. Axon is THE company of 2021/2022!
The start of a federal tsunami!
$FUTU
Novavax $NVAX
Virgin Galactic $SPCE
Plug Power $PLUG
Tata $TTM
Canopy $CGC
$GSX
$WISH
Ballard $BLDP
Moderna $MRNA
Bilibili $BILI
Tencent Music $TME
BioNTech $BNTX
BeiGene $BGNE
$AXON
ViacomCBS $VIAC
Kingsoft $KC
$BYND
$TDOC
Excerpt from AXON's Aug 15 PR... it touts its combo technology with donepezil to advance the SoC by reducing the adverse side effects of donepezil. This is no solution for Alz; it's just trying to make donepezil less bad.
"Axovant and Qaam Pharmaceuticals (Qaam) have entered into an exclusive license agreement under which Axovant expects to develop and, if successful, commercialize products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists including glycopyrrolate, which could mitigate the peripheral side effects of cholinesterase inhibitors. Axovant will initially develop RVT-103, a combination of glycopyrrolate and donepezil. In addition, Axovant expects to develop RVT-104, a combination of glycopyrrolate and high-dose rivastigmine. Axovant believes that the intellectual property portfolio licensed from Qaam as part of this transaction provides a strong exclusivity position in this area."
"This program continues to build on our efforts to deliver comprehensive solutions to patients diagnosed with dementia," said Axovant Chief Development Officer Dr. Lawrence Friedhoff, who led the development of Aricept (donepezil) for the treatment of Alzheimer's disease through its approval in 1996. "We believe this product candidate can limit the peripheral side effects of cholinesterase inhibitors which frequently represent an obstacle for patients to adopt or remain on therapy."
Someone should author a hit piece on AXON revealing the truth about its flawed approach on an ineffective SOC, and post it on MF and SA. Seriously! Would like to give AF, JF, CR and the rest of the cabal, who support this lame company, a taste of their own medicine!
every year this has been biggest scam
changed ticker name 3 times
$AXON
to
$AXGT
to
$SIOX
lost 99.8% share value
225 to 3 dollars